ライフサイエンスコーパス: flucytosine

1 uconazole, itraconazole, amphotericin B, and flucytosine.

2 bated with amphotericin B, itraconazole, and flucytosine.

3 mbination with a low or intermediate dose of flucytosine.

4 ose fluconazole alone or in combination with flucytosine.

5 th fluconazole but no in vivo synergism with flucytosine.

6 atients were treated with amphotericin B and flucytosine.

7 cytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d all resulted in near-maximal ant

8 cytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d.

9 0.7 mg per kilogram per day) with or without flucytosine (100 mg per kilogram per day) for two weeks

10 oxycholate for 4 weeks; (2) amphotericin and flucytosine (100 mg/kg/day) for 2 weeks; and (3) amphote

11 C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates)

12 photericin B (AmB) (87% vs 24%, p<0.001) and flucytosine (5-FC) (57% vs 16%, p<0.001) when indicated.

13 tive effect of the cytosine deaminase (CD)/5-flucytosine (5-FC) gene therapy approach, in which CD co

14 herapy consists of amphotericin B (AmB) plus flucytosine (5-FC), but 5-FC remains largely unavailable

15 otericin B (AMB) induction therapy (6 with 5-flucytosine [5-FC] for a median of 2 weeks); median dura

16 of LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytos

17 de LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytos

18 ketoconazole, 85% for itraconazole, 80% for flucytosine, 77% for terconazole, 66% for miconazole, an

19 amphotericin B, 99.1% and 97%, respectively; flucytosine, 99.1% and 98.8%, respectively; and voricona

20 c relationships were determined for LAmB and flucytosine administered alone.

21 tion antifungal therapy (amphotericin B plus flucytosine) administered before or after inoculation wa

22 Flucytosine administration at clinically meaningful dosi

23 The in vitro and in vivo activity of flucytosine against P. aeruginosa, combined with its des

24 B and C. krusei, itraconazole and C. krusei, flucytosine and C. parapsilosis, fluconazole and C. para

25 s reported identical Etest MICs, the MICs of flucytosine and fluconazole when tested against C. kruse

26 e 202 patients receiving amphotericin B plus flucytosine and in 51 percent of the 179 receiving ampho

27 Flucytosine and itraconazole are the only antifungal age

28 r flucytosine, and VGIII MICs were lower for flucytosine and itraconazole.

29 The VITEK 2 system reliably detected flucytosine and voriconazole resistance among Candida sp

30 ments between the VITEK 2 system and BMD for flucytosine and voriconazole were 98.1 to 98.6% at the 2

31 etermination of MICs of amphotericin B and 5-flucytosine and warrants further evaluation.

32 n monotherapy, $75 121 for amphotericin plus flucytosine, and $44 605 for amphotericin plus fluconazo

33 Resistance to amphotericin B, flucytosine, and fluconazole was < or = 1% overall.

34 tifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazole.

35 isolates were resistant to amphotericin B, 5-flucytosine, and fluconazole.

36 oformans MICs, C. gattii MICs were lower for flucytosine, and VGIII MICs were lower for flucytosine a

37 ates of Candida spp. against amphotericin B, flucytosine, and voriconazole.

38 uconazole and the impact of combination with flucytosine are not known.

39 ment guidelines recommend amphotericin B and flucytosine as first-line induction treatment for crypto

40 Amphotericin B plus flucytosine, as compared with amphotericin B alone, is a

41 Patients in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for

42 traconazole (C. krusei and C. parapsilosis), flucytosine (C. parapsilosis), and fluconazole (C. parap

43 solates for amphotericin B, fluconazole, and flucytosine (Candida parapsilosis ATCC 22019 and Candida

44 to generic drug manufacturer monopolization, flucytosine currently costs approximately $2000 per day

45 he 106 isolates tested, amphotericin B and 5-flucytosine demonstrated the highest agreement in MICs b

46 In a multivariate analysis, the addition of flucytosine during the initial two weeks and treatment w

47 cies-specific ECVs for amphotericin B (AMB), flucytosine (FC) and itraconazole (ITR) for eight Candid

48 ole (I), voriconazole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and amphotericin B (A

49 tes to the antifungal agents amphotericin B, flucytosine, fluconazole, and itraconazole was determine

50 systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole).

51 ungal agents tested included amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, ra

52 determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, vo

53 agents for in vitro testing (amphotericin B, flucytosine, fluconazole, ketoconazole, itraconazole, cl

54 ined the susceptibilities to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, vo

55 The MICs of amphotericin B, flucytosine, fluconazole, voriconazole, posaconazole, an

56 intravenous amphotericin B, with or without flucytosine, followed by therapy with fluconazole.

57 otericin B, fluconazole, itraconazole, and 5-flucytosine for all 106 isolates.

58 h 24-h MICs (92 to 100%) with the azoles and flucytosine for all the species tested, with the excepti

59 recommend treatment with amphotericin B plus flucytosine for at least 2 weeks, followed by fluconazol

60 sulfoxide as the solvent for fluconazole and flucytosine impacted the in vitro potency.

61 trials on the anti-P. aeruginosa efficacy of flucytosine in humans.

62 We found that the antimycotic agent flucytosine inhibits the expression of the iron-starvati

63 tosine deaminase, which converts a prodrug 5-flucytosine into a cytotoxic 5-fluorouracil.

64 , the use of higher-dose amphotericin B plus flucytosine is associated with an increased rate of cere

65 Flucytosine is currently cost-effective in the United St

66 ericin B (LAmB) alone or in combination with flucytosine is not known.

67 Combination therapy with amphotericin and flucytosine is the most attractive treatment strategy fo

68 However, flucytosine is unavailable in Africa and most of Asia, a

69 gal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococc

70 y Etest against amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole in each of f

71 MICs of amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole were determi

72 The MICs of amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole were determi

73 ential and categorical agreement between the flucytosine MIC readings at 48 and 24 h for Candida spec

74 ts < or =1 year old were more susceptible to flucytosine (MIC at which 90% of isolates are inhibited

75 Amphotericin B (MIC(50),1 microg/ml) and flucytosine (MIC(50), 0.12 microg/ml) are both active in

76 to caspofungin (MIC(90), 0.06 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml) and exhibited vari

77 ceptible [S] at a MIC of </=1 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml; 99.2% S) were the

78 s were inhibited [MIC(90)], 4 microg/ml) and flucytosine (MIC(90), 16 microg/ml) were noted, whereas

79 3% of C. albicans isolates were resistant to flucytosine (MIC, > or = 32 microg/ml), compared to < 1%

80 Susceptibility to flucytosine (MIC, < or = 4 microg/ml) increased from 34%

81 Susceptibility to flucytosine (MIC, < or = 4 microg/ml) ranged from 35% in

82 Comparison of the flucytosine MICs obtained with RPMI 1640 medium revealed

83 oriconazole and to have significantly higher flucytosine MICs than C. glabrata strains.

84 mphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available.

85 trolled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amph

86 r antifungal agents, such as amphotericin B, flucytosine, or itraconazole.

87 Both LAmB and flucytosine produced a dose-dependent reduction in funga

88 ysis was performed to determine the value of flucytosine relative to alternative regimens.

89 fluconazole-resistant isolates (3%) and one flucytosine-resistant isolate (1%) as susceptible, repre

90 ble to the majority of antifungals, and only flucytosine showed poor antifungal activity.

91 The flucytosine susceptibility results indicated that strain

92 onazole-susceptible isolates (3%), and three flucytosine-susceptible isolates (4%), representing 12 m

93 among patients receiving amphotericin B and flucytosine than among those receiving amphotericin B al

94 and insufficiently coordinated distribution; flucytosine through cost and scarcity of registration; a

95 The daily flucytosine treatment cost in the United Kingdom is appr

96 per day in the United States, with a 2-week flucytosine treatment course costing approximately $28 0

97 The ICER of amphotericin plus flucytosine was $23 842 per quality-adjusted life-year.

98 Amphotericin B plus flucytosine was associated with significantly increased

99 Resistance to fluconazole and flucytosine was observed infrequently (3.7% and 3.0%); 1

100 nazole in combination with intermediate-dose flucytosine were effective in reducing CSF cryptococcal